Lactate-Driven HMGB1 Modification and Exosomal Release in Sepsis

Study Background and Research Question

Sepsis, a life-threatening syndrome characterized by dysregulated inflammation and organ dysfunction, remains a major cause of mortality worldwide. Clinical guidelines increasingly rely on serum lactate as a prognostic biomarker, with persistent levels >2 mmol/L linked to poor outcomes (source: paper). However, beyond its role as a marker, whether lactate acts as an active driver of inflammatory processes in sepsis has remained poorly defined. High mobility group box-1 (HMGB1), a nuclear protein released by macrophages, orchestrates late-phase inflammation and has been shown to correlate with sepsis severity. The current study addresses a critical mechanistic question: does lactate directly promote HMGB1 modification and release during polymicrobial sepsis?

Key Innovation from the Reference Study

The central innovation of this research is the demonstration that extracellular lactate is not merely a bystander but actively modifies HMGB1 via two post-translational mechanisms—lactylation and acetylation—in macrophages. This dual modification enhances HMGB1 release in exosomes, linking metabolic changes to amplified inflammatory signaling in sepsis. Notably, the study identifies distinct signaling axes: p300/CBP-dependent pathways mediate lactylation, while acetylation arises from a combination of Hippo/YAP-mediated SIRT1 suppression and β-arrestin2-facilitated nuclear recruitment of acetylases via GPR81 (source: paper).

Methods and Experimental Design Insights

The authors used a combination of in vivo, ex vivo, and in vitro approaches to dissect the link between lactate and HMGB1 modification. Key elements include:

• Animal Models: Wild-type, YAP conditional knockout, and Cre/loxP-modified mice subjected to cecal ligation and puncture (CLP) to induce polymicrobial sepsis.
• Biochemical Analyses: Immunoprecipitation and immunoblotting to detect lactylation and acetylation of HMGB1 in macrophage lysates.
• Exosome Isolation: Serum exosomes were isolated and characterized to quantify HMGB1 content and assess their impact on endothelial permeability.
• Pharmacological Manipulation: Inhibitors targeting lactate production (e.g., glycolysis inhibitors) and GPR81 signaling were employed to test reversibility of HMGB1 exosomal release.
• Genetic Approaches: Use of macrophage-specific YAP knockout mice to probe the Hippo pathway’s role in HMGB1 acetylation.
• Correlation Analyses: Mouse and human serum samples were analyzed for lactate and HMGB1 correlation, supporting translational relevance.

These approaches enabled precise mapping of causal relationships and elucidation of the molecular machinery involved in HMGB1 release (source: paper).

Core Findings and Why They Matter

• Lactate Drives HMGB1 Modification: Elevated extracellular lactate is taken up by macrophages via monocarboxylate transporters (MCTs), fueling p300/CBP-dependent lactylation of HMGB1. Concurrently, lactate, through GPR81 activation, suppresses SIRT1 (a deacetylase) via the Hippo/YAP pathway and enhances acetylation via β-arrestin2-mediated acetylase recruitment.
• Enhanced Exosomal HMGB1 Release: The dual-modified HMGB1 is preferentially sorted into exosomes and released from macrophages, significantly raising serum exosomal HMGB1 levels in septic mice. These exosomes increase endothelial permeability, a hallmark of septic organ dysfunction (source: paper).
• Intervention Reduces Pathology: Inhibiting lactate production or blocking GPR81 signaling led to lower circulating HMGB1 and improved survival in septic mice, highlighting the potential of targeting lactate signaling in inflammatory signaling pathway research and therapeutic development.

This mechanistic insight bridges cellular metabolism with inflammatory mediator release, shedding light on why lactate may be both a marker and a driver of poor sepsis outcomes.

Comparison with Existing Internal Articles

Several internal resources contextualize this study within broader inflammatory and apoptosis regulation research:

• Bay 11-7821 (BAY 11-7082): Precision IKK Inhibition for Translational Studies discusses the intersection of NF-κB pathway inhibition and HMGB1/lactate signaling. The present study’s focus on lactate-driven HMGB1 release complements analyses of how IKK/NF-κB inhibition can modulate downstream inflammatory responses, suggesting new experimental strategies for dissecting pathway cross-talk.
• Bay 11-7821: Novel Insights into NF-κB Pathway Inhibition explores the experimental use of NF-κB pathway inhibitors in the context of lactate-mediated inflammation. The current findings reinforce the value of integrating metabolic modulation and pathway-specific inhibition in apoptosis regulation study designs.
• Bay 11-7821 (BAY 11-7082): A Benchmark IKK & NF-κB Pathway Tool provides structured evidence for the compound’s use in inflammatory signaling pathway research, which is highly relevant for follow-up studies examining the impact of HMGB1 modulation on macrophage and endothelial cell behavior.

Collectively, these resources underscore experimental strategies for targeting both upstream (IKK/NF-κB) and metabolic (lactate/HMGB1) axes in B-cell lymphoma research, cancer research, and inflammation models.

Limitations and Transferability

While the study provides compelling evidence for a lactate-HMGB1 axis in murine models, several caveats merit consideration:

• Species Differences: Most experiments were performed in mice; while human serum data support relevance, further validation in human macrophages and clinical samples is needed to fully translate these findings (source: paper).
• Pathway Complexity: Although the study elegantly dissects key signaling routes (p300/CBP, SIRT1, YAP, GPR81), other pathways may contribute to HMGB1 modification and release, warranting further mechanistic exploration.
• Therapeutic Targeting: Pharmacological inhibitors were used to probe reversibility; however, the specificity and safety of such agents in clinical contexts require careful evaluation.
• Transferability: The mechanistic insights are most directly transferable to applications in inflammatory signaling pathway research and apoptosis regulation study, but require adaptation for other disease contexts (workflow_recommendation).

Protocol Parameters

• in vitro macrophage HMGB1 release assay | 2–10 mM lactate | sepsis/inflammation models | reflects pathophysiological lactate concentrations | paper
• in vivo CLP sepsis model | 1–2 mmol/L serum lactate threshold | murine survival prediction | matches clinical sepsis cutoffs | paper
• IKK/NF-κB inhibition (Bay 11-7821) | 1–10 μM | cell-based inflammation/apoptosis assays | standard range for pathway inhibition; supports synergy studies with metabolic modulators | product_spec
• exosome isolation | ultracentrifugation (100,000 x g) | serum/cell culture | standard for exosomal protein quantification | workflow_recommendation

Research Support Resources

Investigators aiming to expand on these findings can leverage selective pathway inhibitors and robust cell-based assays. Bay 11-7821 (BAY 11-7082) (SKU A4210) from APExBIO is a well-characterized IκB kinase (IKK) inhibitor that blocks NF-κB activation and downstream inflammatory gene expression (source: product_spec). This compound is widely used in apoptosis regulation and inflammatory signaling pathway research, including studies integrating metabolic modulators such as lactate. The compound’s solubility profile and validated use in both in vitro and in vivo models facilitate its integration into workflows based on the present reference study. For additional optimization strategies, internal resources provide scenario-driven guidance on assay design and data reproducibility (source: workflow_recommendation).